Literature DB >> 22800582

PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin.

Brijeshkumar Patel1, Vivek Gupta, Fakhrul Ahsan.   

Abstract

This study was designed to evaluate the feasibility of PEG-PLGA copolymers as carriers for pulmonary delivery of a highly soluble drug. We attempt to address the limitations of low entrapment efficiencies and poor release profiles that are associated with the use of conventional PLGAs. We have used low molecular weight heparin (LMWH) as a model for highly soluble and ionizable drugs and a 3 × 3 full factorial design to prepare nine formulations. We considered polymer type and percent NaCl in external phase as two independent variables at three different levels; the levels for polymer type were PLGA, PEG-PLGA and PLGA-PEG-PLGA and that for percent NaCl were 0%, 5% and 8%. Formulations were characterized for various physical properties, respirability, drug release, and evaluated for in vivo absorption, alveolar uptake, and safety. Statistical analyses suggest that both polymer type and salt concentration influenced the morphology and micromeritic properties of the particles. Compared with PLGA, PEG-PLGA copolymers produced inherently larger porous particles with high drug entrapment and a greater extent of drug release. Moreover, addition of NaCl in the external phase maximized drug entrapment but minimized burst release and produced smaller and denser particles. Fluorescent PEG-PLGA particles showed reduced uptake by alveolar macrophages, and exhibited a uniform distribution in the lungs compared with PLGA particles. Further, ~85% of the particles were cleared off the lungs within 6 days. Intratracheally administered PEG-PLGA based optimized formulation exhibited a biological half-life of 18.64 h, which was ~4.5 times longer than plain LMWH. No cytotoxic effect was observed when bronchial epithelial cells were incubated with PEG-PLGA based formulations. Similarly, no increase in the injury markers was observed in the bronchoalveolar lavage fluids collected from rats treated with PEG-PLGA particles of LMWH. Overall, this study suggests that PEG-PLGA block copolymers have the potential to be developed as efficient and biocompatible carriers for pulmonary delivery of highly water-soluble drugs.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22800582     DOI: 10.1016/j.jconrel.2012.07.003

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  28 in total

1.  Vasoactive effects of stable aqueous suspensions of single walled carbon nanotubes in hamsters and mice.

Authors:  Mary D Frame; Anthony M Dewar; Sayan Mullick Chowdhury; Balaji Sitharaman
Journal:  Nanotoxicology       Date:  2013-09-30       Impact factor: 5.913

2.  Peptide-micelle hybrids containing fasudil for targeted delivery to the pulmonary arteries and arterioles to treat pulmonary arterial hypertension.

Authors:  Nilesh Gupta; Hany M Ibrahim; Fakhrul Ahsan
Journal:  J Pharm Sci       Date:  2014-09-29       Impact factor: 3.534

3.  Distribution and Cellular Uptake of PEGylated Polymeric Particles in the Lung Towards Cell-Specific Targeted Delivery.

Authors:  Tammy W Shen; Catherine A Fromen; Marc P Kai; J Christopher Luft; Tojan B Rahhal; Gregory R Robbins; Joseph M DeSimone
Journal:  Pharm Res       Date:  2015-05-23       Impact factor: 4.200

4.  Inhaled combination of sildenafil and rosiglitazone improves pulmonary hemodynamics, cardiac function, and arterial remodeling.

Authors:  Jahidur Rashid; Eva Nozik-Grayck; Ivan F McMurtry; Kurt R Stenmark; Fakhrul Ahsan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-10-11       Impact factor: 5.464

5.  Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH).

Authors:  Jahidur Rashid; Brijeshkumar Patel; Eva Nozik-Grayck; Ivan F McMurtry; Kurt R Stenmark; Fakhrul Ahsan
Journal:  J Control Release       Date:  2017-02-07       Impact factor: 9.776

6.  Low-molecular-weight heparin (LMWH)-loaded large porous PEG-PLGA particles for the treatment of asthma.

Authors:  Brijeshkumar Patel; Nilesh Gupta; Fakhrul Ahsan
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-11-28       Impact factor: 2.849

7.  Repurposing rosiglitazone, a PPAR-γ agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH.

Authors:  Jahidur Rashid; Ahmad Alobaida; Taslim A Al-Hilal; Samia Hammouda; Ivan F McMurtry; Eva Nozik-Grayck; Kurt R Stenmark; Fakhrul Ahsan
Journal:  J Control Release       Date:  2018-04-30       Impact factor: 9.776

8.  Aerosolized montelukast polymeric particles-an alternative to oral montelukast-alleviate symptoms of asthma in a rodent model.

Authors:  Brijeshkumar Patel; Nilesh Gupta; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2014-06-17       Impact factor: 4.200

9.  Starch-coated magnetic liposomes as an inhalable carrier for accumulation of fasudil in the pulmonary vasculature.

Authors:  Kamrun Nahar; Shahriar Absar; Brijeshkumar Patel; Fakhrul Ahsan
Journal:  Int J Pharm       Date:  2014-01-21       Impact factor: 5.875

10.  Inhaled PLGA particles of prostaglandin E₁ ameliorate symptoms and progression of pulmonary hypertension at a reduced dosing frequency.

Authors:  Vivek Gupta; Nilesh Gupta; Imam H Shaik; Reza Mehvar; Eva Nozik-Grayck; Ivan F McMurtry; Masahiko Oka; Masanobu Komatsu; Fakhrul Ahsan
Journal:  Mol Pharm       Date:  2013-03-26       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.